Introduction & Classification - Cancer Detectives
- Tumor Markers: Substances (proteins, enzymes, hormones) from cancer cells or body's response. Uses: aid diagnosis, stage, prognose, monitor therapy, detect recurrence. Limited for screening.
- Ideal Characteristics: 📌 SENSITIVE & SPECIFIC
- High sensitivity & specificity
- Correlates with tumor burden
- Reflects therapy response
- Predicts recurrence
- Easy, cost-effective
- Classification:
Category Examples Primary Association(s) Enzymes PSA, NSE Prostate, Neuroendocrine Hormones hCG, Calcitonin Germ Cell, Medullary Thyroid Ca Oncofetal Ag AFP, CEA Liver/Germ Cell, GI Cancers Carbohydrate Ag CA 125, CA 19-9 Ovarian, Pancreatic
⭐ Most tumor markers lack sufficient specificity for widespread population screening; they are primarily valuable for monitoring disease progression or recurrence in diagnosed patients.
Common Markers: Set 1 - Key Player Trio
| Marker | Primary Associated Cancer(s) | Other Associations/Key Clinical Notes |
|---|---|---|
| AFP | Hepatocellular Carcinoma (HCC), Non-seminomatous germ cell tumors (NSGCT) e.g., yolk sac tumor | 📌 A Foetus Protein. ↑ Physiological (pregnancy), pathological (neural tube defects, ataxia-telangiectasia). Normal: <10 ng/mL. Monitoring therapy & recurrence. |
| β-hCG | Choriocarcinoma, Germ cell tumors (seminomatous & NSGCT), Hydatidiform mole | ↑ Normal pregnancy. β-subunit is specific. Used for diagnosis, prognosis, and monitoring response to therapy. |
| PSA | Prostate Cancer | Organ-specific (prostate tissue), not cancer-specific. ↑ Benign Prostatic Hyperplasia (BPH), prostatitis, post-DRE. Levels: <4 ng/mL normal, 4-10 ng/mL grey zone, >10 ng/mL high risk. Screening, staging aid, monitoring. |
Common Markers: Set 2 - CA & Hormonal IDs
| Marker | Primary Associated Cancer(s) | Other Associations/Key Clinical Notes |
|---|---|---|
| CA-125 | Ovarian (epithelial) 📌 | Monitor response/recurrence. Normal <35 U/mL. Also ↑ in endometriosis, PID, pregnancy. |
| CA 19-9 | Pancreatic, GI 📌 | Cholangiocarcinoma. Monitor. Lewis (a-/b-) non-expressors. |
| CA 15-3/27.29 | Breast (metastatic) 📌 | Monitor therapy/recurrence. Also ↑ in benign breast disease, ovarian, lung cancer. |
| hCG | GTD, Germ cell tumors (testicular, ovarian) | β-hCG specific. Pregnancy detection. |
| Calcitonin | Medullary Thyroid Carcinoma (MTC) | Screening in MEN2 syndromes. Post-op monitoring for recurrence. |
Clinical Application - Uses & Cautions
Uses (📌 SAD PMR):
- Screening: Limited (e.g., PSA in high-risk groups).
- Aid Diagnosis: Supplements clinical/imaging findings; not standalone.
- Prognosis: Levels may correlate with tumor burden/aggressiveness.
- Monitoring Therapy: Assess treatment response (serial measurements).
- Detecting Recurrence: Early indicator of relapse post-treatment.
Limitations/Cautions:
- Low sensitivity: False negatives, especially in early-stage disease.
- Low specificity: False positives due to benign conditions (e.g., inflammation, smoking), physiological states.
- Not all patients with a specific cancer show elevated markers.
- Marker levels may not always correlate with tumor size or stage.
- Hook effect (very high concentrations can give falsely low readings).
⭐ Serial measurements of a tumor marker are often more informative than a single value, reflecting trends over time.
High‑Yield Points - ⚡ Biggest Takeaways
- AFP: For hepatocellular carcinoma & yolk sac tumors (non-seminomatous GCT).
- β-hCG: For choriocarcinoma, moles, & many testicular germ cell tumors.
- CEA: Monitors colorectal cancer recurrence; also in other adenocarcinomas.
- CA-125: Tracks ovarian cancer (epithelial) response and detection.
- CA 19-9: For pancreatic cancer & cholangiocarcinoma; aids prognosis.
- PSA: Screens, diagnoses, & monitors prostate cancer activity.
- Calcitonin: Highly specific for medullary thyroid carcinoma; screens MEN2_family_members_._
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app
